Skip to search formSkip to main contentSkip to account menu

satavaptan

Known as: Benzamide, N-(1,1-dimethylethyl)-4-((cis-5'-ethoxy-4-(2-(4-morpholinyl)ethoxy)-2'-oxospiro(cyclohexane-1,3'-(3H)indol)-1'(2'H)-yl)sulfonyl)-3-methoxy- 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

MorpholinesSpiro CompoundsVasopressin Antagonist

Narrower (3)

SR 121463SR 121463ASR-121463B

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Chapter 43 - Miscellaneous Hormones
Review
2012
Review
2012
43 - Miscellaneous hormones
Review
2010
Review
2010
An overview of satavaptan: a selective V2 receptor antagonist
Satavaptan is a new selective V2 receptor antagonist that shares the aquaretic effect of the other arginine vasopressin… 
Review
2010
Review
2010
[Vasopressin receptor antagonists: the vaptans].
2009
2009
102 EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY
Review
2008
Review
2008
Mechanisms, Risks, and New Treatment Options for Hyponatremia
Hyponatremia is the most common electrolyte abnormality in hospitalized patients and is associated with increased mortality… 
2008
2008
A hyponatraemiás állapotok etiológiája, diagnosztikája és terápiája
A tanulmány klinikusok számára foglalja össze a hyponatraemiák kóroktanát, diagnosztikáját és kezelését. A hyponatraemia a… 
Review
2007
Review
2007
V2-antagonists for the treatment of hyponatraemia.
Hypotonic hyponatraemia results from an excess of total body water relative to the exchangeable sodium and potassium pool due to… 
2007
2007
[90] LONG-TERM IMPROVEMENT OF SERUM SODIUM BY THE V-RECEPTOR ANTAGONIST SATAVAPTAN IN PATIENTS WITH CIRRHOSIS AND HYPONATRAEMIA
Review
2007
Review
2007
[Vasopressin antagonists in treatment of hyponatremia].
Hyponatremia is the most frequently encountered electrolyte disturbance in hospitalized patients. It is usually caused by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)